Time & Date: 1 September, 14:45 – 15:45 CEST
Chairpersons: D. Fischer UK & I. Audo FRANCE
Speakers & Presentations:
I. Audo FRANCE
14:45 Welcome
N. Paudel IRELAND
14:47 Genetic testing experiences of people living with inherited retinal diseases (IRDs) – results of a global survey
I. Audo FRANCE
14:53 RLIGHT – Observational study on the use of voretigene neparvovec (VN) in patients with inherited retinal dystrophy (IRD) at CHNO des Quinze-Vingts: a 1-year follow-up safety and efficacy results
D. Fischer UK
14:59 Real-world safety and effectiveness of voretigene neparvovec: Year 2 interim results from the PERCEIVE study
V. Gonzalez USA
15:05 Development of Novel Endpoints for the Study of Multi-Characteristic Opsin Enabled Vision Restoration in Patients with Advanced Retinitis Pigmentosa; Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study
J. Wawrzynski UK
15:11 Intravitreal Cerliponase alfa for the treatment of Neuronal Ceroid Lipofuscinosis type 2 (CLN2) related retinal dystrophy: A first in man report of ocular enzyme replacement.
S.N Geada Batista PORTUGAL
15:17 Expanding the mutational spectrum of CNGB1-associated RP-olfactory dysfunction syndrome
L. Mautone GERMANY
15:23 Diurnal changes of macular anatomy and sensitivity in X-linked juvenile retinoschisis
H. Baran Özdemir TURKEY
15:29 Congenital X-Linked Retinoschisis: Surgical Needs and Outcomes in Long Term. A Retrospective Multicenter International Study
M. Mateos SPAIN
15:35 Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients
All Faculty
15:41 Discussion
